Steffan987

Name	:	steffan987
Website	:	Visit Website
Blog	:	Visit Blog
Social Links	:

Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 [Up

Steffan98707 Sep, 2021Health

The ?Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031? report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Neurotrophic Keratitis.

Abscess: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 [Upcoming Report]

Steffan98707 Sep, 2021Health

The ?Abscess: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031? report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Abscess. This report provides an in-depth analysis of the product pipeline and developer companies,

Glycosylation Analysis Services Market by Company Size (Small, Mid- sized and Large)

Steffan98731 Aug, 2021Health

The ?Glycosylation Analysis Services Market, 2021- 2030? report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the market, over the next decade. The study underlines an in-depth analysis of the various services offered for assessing glycosylation related attributes

Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2

Steffan98731 Aug, 2021Health

The ?Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031? report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of polycystic ovarian syndrome.

Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer

Steffan98717 Aug, 2021Health

The ?Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized and Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030?

Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics

Steffan98727 Jul, 2021Health

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry. In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025

Erythropoietic Protoporphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2

Steffan98720 Jul, 2021Health

In the coming years, the market is anticipated to grow at a significant pace owing to the rising awareness of the disease and increasing interest of stakeholders to invest in this field. More novel therapy solutions are being developed by various industry as well as non-industry stakeholders

3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035

Steffan98706 Jul, 2021Photography

Over 70 bioprinters are currently either commercialized or under development; of these, close to 75% have been developed by industry players. Examples of commercialized 3D bioprinters by industry stakeholders include (in alphabetical order) 3D-Bioplotter? Series

Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030

Steffan98706 Jul, 2021Health

Over 25 unique non-antibody protein scaffolds have been developed for the generation of different product candidates. Notable examples include (in alphabetical order)Affibody? (Affibody), Affimer? (Avacta), Anticalin? (Pieris Pharmaceuticals), AdnectinTM (BMS), Bicycles? (Bicycle Therapeutics), DARPin? (Molecular Partners), Kunitz Domain (Shire) and Nanofitin? (Affilogic).

Antibody Drug Conjugates Market (4th Edition), 2017-2030

Steffan98706 Jul, 2021Health

Close to 50% of the total ADC clinical trials (completed / recruiting) are evaluating ADCs in combination with other therapies. In the last two years, several novel combinations have been studied with ADCs; these include combinations with PI3K inhibitors, TYK inhibitors, BTK inhibitors, CDK inhibitors, HDAC inhibitors and EGFR inhibitors